{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T17:18:51Z","timestamp":1790011131323,"version":"4.0.1"},"reference-count":41,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","jni-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Neuroimmunology"],"published-print":{"date-parts":[[2024,11]]},"DOI":"10.1016\/j.jneuroim.2024.578463","type":"journal-article","created":{"date-parts":[[2024,10,4]],"date-time":"2024-10-04T20:50:49Z","timestamp":1728075049000},"page":"578463","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"special_numbering":"C","title":["Effectiveness of double-filtration plasmapheresis in reducing immunoglobulin and culprit antibody levels in neuroimmune disorders: A single-center retrospective analysis from China"],"prefix":"10.1016","volume":"396","author":[{"given":"Yan","family":"Lin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiajun","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yufang","family":"Mei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liping","family":"Ni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huiying","family":"Qiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenbin","family":"Wan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jneuroim.2024.578463_bb0005","first-page":"406","article-title":"Double filtration plasmapheresis","volume":"26","author":"Agishi","year":"1980","journal-title":"Trans. Am. Soc. Artificial Internal Organs"},{"key":"10.1016\/j.jneuroim.2024.578463_bb0010","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaut.2019.102339","article-title":"The immunobiology of autoimmune encephalitides","volume":"104","author":"Alexopoulos","year":"2019","journal-title":"J. Autoimmun."},{"key":"10.1016\/j.jneuroim.2024.578463_bb0015","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1159\/000528556","article-title":"Therapeutic plasmapheresis: a revision of literature","volume":"48","author":"Altobelli","year":"2022","journal-title":"Kidney Blood Press. Res."},{"key":"10.1016\/j.jneuroim.2024.578463_bb0020","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2018.4169","article-title":"Association of immunoglobulin levels, infectious risk, and mortality with rituximab and Hypogammaglobulinemia","volume":"1","author":"Barmettler","year":"2018","journal-title":"JAMA Netw. Open"},{"key":"10.1016\/j.jneuroim.2024.578463_bb0025","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2021.664664","article-title":"Autoimmune disorders of the nervous system: pathophysiology, clinical features, and therapy","volume":"12","author":"Bhagavati","year":"2021","journal-title":"Front. Neurol."},{"key":"10.1016\/j.jneuroim.2024.578463_bb0030","first-page":"9","article-title":"IgG4-mediated neurologic autoimmunities: understanding the pathogenicity of IgG4, ineffectiveness of IVIg, and long-lasting benefits of anti-B cell therapies","author":"Dalakas","year":"2022","journal-title":"Neurol. (R) Neuroimmunol. & Neuroinflam."},{"key":"10.1016\/j.jneuroim.2024.578463_bb0035","doi-asserted-by":"crossref","DOI":"10.1016\/j.jneuroim.2023.578071","article-title":"Autoimmune encephalitis misdiagnosis and mimics","volume":"378","author":"Dinoto","year":"2023","journal-title":"J. Neuroimmunol."},{"key":"10.1016\/j.jneuroim.2024.578463_bb0040","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1111\/ene.13819","article-title":"Multiple sclerosis - a review","volume":"26","author":"Dobson","year":"2019","journal-title":"Eur. J. Neurol."},{"key":"10.1016\/j.jneuroim.2024.578463_bb0045","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/S1474-4422(15)00401-9","article-title":"A clinical approach to diagnosis of autoimmune encephalitis","volume":"15","author":"Graus","year":"2016","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.jneuroim.2024.578463_bb0050","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1002\/jca.10023","article-title":"Long-term treatment of myasthenia gravis with immunoadsorption","volume":"17","author":"Haas","year":"2002","journal-title":"J. Clin. Apher."},{"key":"10.1016\/j.jneuroim.2024.578463_bb0055","doi-asserted-by":"crossref","first-page":"2395","DOI":"10.1007\/s00415-016-8277-y","article-title":"Immunoadsorption or plasma exchange in the treatment of autoimmune encephalitis: a pilot study","volume":"263","author":"Heine","year":"2016","journal-title":"J. Neurol."},{"key":"10.1016\/j.jneuroim.2024.578463_bb0060","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1111\/1744-9987.13548","article-title":"Double filtration plasmapheresis: review of current clinical applications","volume":"25","author":"Hirano","year":"2021","journal-title":"Ther. Apher. Dial."},{"key":"10.1016\/j.jneuroim.2024.578463_bb0065","doi-asserted-by":"crossref","first-page":"1110499","DOI":"10.3389\/fimmu.2023.1110499","article-title":"Inflammation and autoimmune myasthenia gravis","volume":"14","author":"Huda","year":"2023","journal-title":"Front. Immunol."},{"key":"10.1016\/j.jneuroim.2024.578463_bb0070","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1186\/s41100-021-00379-z","article-title":"Novel double-filtration plasmapheresis preserves fibrinogen while removing immunoglobulin-G antibodies before ABO blood type-incompatible kidney transplantation","volume":"7","author":"Iwami","year":"2021","journal-title":"Renal Replacement Therapy"},{"key":"10.1016\/j.jneuroim.2024.578463_bb0075","doi-asserted-by":"crossref","first-page":"377","DOI":"10.4103\/ijn.IJN_64_17","article-title":"Effect of double filtration plasmapheresis on various plasma components and patient safety: a prospective observational cohort study","volume":"27","author":"Jagdish","year":"2017","journal-title":"Ind. J. Nephrol."},{"key":"10.1016\/j.jneuroim.2024.578463_bb0080","first-page":"14","article-title":"Successful treatment of positive-sense RNA virus coinfection with autoimmune hepatitis using double filtration plasmapheresis","author":"Kamimura","year":"2021","journal-title":"BMJ Case Rep."},{"key":"10.1016\/j.jneuroim.2024.578463_bb0085","doi-asserted-by":"crossref","DOI":"10.7754\/Clin.Lab.2021.211051","article-title":"Double filtration plasmapheresis (DFPP) in severe hypertriglyceridemia patients - a pilot study","volume":"68","author":"Lei","year":"2022","journal-title":"Clin. Lab."},{"key":"10.1016\/j.jneuroim.2024.578463_bb0090","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1111\/j.1744-9987.2009.00751.x","article-title":"Comparing the autoantibody levels and clinical efficacy of double filtration plasmapheresis, immunoadsorption, and intravenous immunoglobulin for the treatment of late-onset myasthenia gravis","volume":"14","author":"Liu","year":"2010","journal-title":"Ther. Apher. Dial."},{"key":"10.1016\/j.jneuroim.2024.578463_bb0095","article-title":"Editorial: immune mechanisms in the pathologic response to particles, fibers, and nanomaterials","volume":"12","author":"Ma","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.jneuroim.2024.578463_bb0100","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1016\/j.transci.2017.08.009","article-title":"Double filtration plasmapheresis: determination of the optimal albumin concentration in the supplementation fluid","volume":"56","author":"Mineshima","year":"2017","journal-title":"Transfus. Apher. Sci."},{"key":"10.1016\/j.jneuroim.2024.578463_bb0105","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1046\/j.1526-0968.2002.00428.x","article-title":"Double filtration plasmapheresis in critical care","volume":"6","author":"Mineshima","year":"2002","journal-title":"Ther. Apher."},{"key":"10.1016\/j.jneuroim.2024.578463_bb0110","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2021.103019","article-title":"Efficacy of intravenous immunoglobulin in autoimmune neurological diseases. Literature systematic review and meta-analysis","volume":"21","author":"Morales-Ruiz","year":"2022","journal-title":"Autoimmun. Rev."},{"key":"10.1016\/j.jneuroim.2024.578463_bb0115","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1016\/j.jocn.2010.07.141","article-title":"Therapeutic efficacy of double filtration plasmapheresis in patients with anti-aquaporin-4 antibody-positive multiple sclerosis","volume":"18","author":"Munemoto","year":"2011","journal-title":"J. Clin. Neurosci."},{"key":"10.1016\/j.jneuroim.2024.578463_bb0120","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1212\/WNL.0000000000011124","article-title":"International consensus guidance for Management of Myasthenia Gravis: 2020 update","volume":"96","author":"Narayanaswami","year":"2021","journal-title":"Neurology"},{"key":"10.1016\/j.jneuroim.2024.578463_bb0125","doi-asserted-by":"crossref","DOI":"10.4414\/SMW.2022.w30088","article-title":"Short-term glucocorticoid-related side effects and adverse reactions: a narrative review and practical approach","volume":"152","author":"Noetzlin","year":"2022","journal-title":"Swiss Med. Wkly."},{"key":"10.1016\/j.jneuroim.2024.578463_bb0130","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1385\/CRIAI:29:3:173","article-title":"Intravenous immunoglobulin: adverse effects and safe administration","volume":"29","author":"Orbach","year":"2005","journal-title":"Clin. Rev. Allergy Immunol."},{"key":"10.1016\/j.jneuroim.2024.578463_bb0135","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1002\/jca.21705","article-title":"Guidelines on the use of therapeutic apheresis in clinical practice - evidence-based approach from the writing Committee of the American Society for apheresis: the eighth special issue","volume":"34","author":"Padmanabhan","year":"2019","journal-title":"J. Clin. Apher."},{"key":"10.1016\/j.jneuroim.2024.578463_bb0140","first-page":"9","article-title":"Hypogammaglobulinemia and infections in patients with multiple sclerosis treated with rituximab","author":"Perriguey","year":"2022","journal-title":"Neurol. (R) Neuroimmunol. & Neuroinflam."},{"key":"10.1016\/j.jneuroim.2024.578463_bb0145","first-page":"621","article-title":"Therapeutic plasma exchange and double filtration plasmapheresis in severe NEUROIMMUNE disorders","volume":"58","author":"Roman-Filip","year":"2019","journal-title":"Acta Clin. Croat."},{"key":"10.1016\/j.jneuroim.2024.578463_bb0150","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/j.amjmed.2017.10.033","article-title":"Autoimmune Neurologic Disorders","volume":"131","author":"Rubin","year":"2018","journal-title":"Am. J. Med."},{"key":"10.1016\/j.jneuroim.2024.578463_bb0155","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1212\/WNL.0000000000002790","article-title":"International consensus guidance for management of myasthenia gravis: executive summary","volume":"87","author":"Sanders","year":"2016","journal-title":"Neurology"},{"key":"10.1016\/j.jneuroim.2024.578463_bb0160","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1016\/S0140-6736(21)00517-1","article-title":"Guillain-Barr\u00e9 syndrome","volume":"397","author":"Shahrizaila","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.jneuroim.2024.578463_bb0165","doi-asserted-by":"crossref","first-page":"4549","DOI":"10.1007\/s00415-020-10257-z","article-title":"Therapeutic plasma exchange vs conventional treatment with intravenous high dose steroid for neuromyelitis optica spectrum disorders (NMOSD): a systematic review and meta-analysis","volume":"268","author":"Siritho","year":"2021","journal-title":"J. Neurol."},{"key":"10.1016\/j.jneuroim.2024.578463_bb0170","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1111\/1744-9987.13595","article-title":"Sequential intermittent therapeutic plasma exchange: a possible induction and maintenance therapy in the management of adult patients with neuromyelitis optica spectrum disorder","volume":"25","author":"Viswanathan","year":"2021","journal-title":"Ther. Apher. Dial."},{"key":"10.1016\/j.jneuroim.2024.578463_bb0175","doi-asserted-by":"crossref","first-page":"1785","DOI":"10.3389\/fimmu.2017.01785","article-title":"Immunopathogenesis in myasthenia gravis and Neuromyelitis Optica","volume":"8","author":"Wang","year":"2017","journal-title":"Front. Immunol."},{"key":"10.1016\/j.jneuroim.2024.578463_bb0180","doi-asserted-by":"crossref","first-page":"126","DOI":"10.2144\/btn-2019-0031","article-title":"Best practices in bioassay development to support registration of biopharmaceuticals","volume":"67","author":"White","year":"2019","journal-title":"BioTechniques"},{"key":"10.1016\/j.jneuroim.2024.578463_bb0185","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1212\/WNL.0000000000001729","article-title":"International consensus diagnostic criteria for neuromyelitis optica spectrum disorders","volume":"85","author":"Wingerchuk","year":"2015","journal-title":"Neurology"},{"key":"10.1016\/j.jneuroim.2024.578463_bb0190","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1182\/asheducation.V2012.1.7.3797920","article-title":"Plasma exchange: concepts, mechanisms, and an overview of the American Society for Apheresis guidelines","volume":"2012","author":"Winters","year":"2012","journal-title":"Hematology"},{"key":"10.1016\/j.jneuroim.2024.578463_bb0195","doi-asserted-by":"crossref","first-page":"1108738","DOI":"10.3389\/fneur.2023.1108738","article-title":"The role of the gut microbiota and fecal microbiota transplantation in neuroimmune diseases","volume":"14","author":"Wu","year":"2023","journal-title":"Front. Neurol."},{"key":"10.1016\/j.jneuroim.2024.578463_bb0200","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1002\/jca.21377","article-title":"Maintenance plasma exchange treatment for muscle specific kinase antibody positive myasthenia gravis patients","volume":"30","author":"Yamada","year":"2015","journal-title":"J. Clin. Apher."},{"key":"10.1016\/j.jneuroim.2024.578463_bb0205","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1016\/j.jocn.2013.11.046","article-title":"Double filtration plasmapheresis benefits myasthenia gravis patients through an immunomodulatory action","volume":"21","author":"Zhang","year":"2014","journal-title":"J. Clin. Neurosci."}],"container-title":["Journal of Neuroimmunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165572824001826?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165572824001826?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,11,13]],"date-time":"2024-11-13T02:58:07Z","timestamp":1731466687000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0165572824001826"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11]]},"references-count":41,"alternative-id":["S0165572824001826"],"URL":"https:\/\/doi.org\/10.1016\/j.jneuroim.2024.578463","relation":{},"ISSN":["0165-5728"],"issn-type":[{"value":"0165-5728","type":"print"}],"subject":[],"published":{"date-parts":[[2024,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effectiveness of double-filtration plasmapheresis in reducing immunoglobulin and culprit antibody levels in neuroimmune disorders: A single-center retrospective analysis from China","name":"articletitle","label":"Article Title"},{"value":"Journal of Neuroimmunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jneuroim.2024.578463","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"578463"}}